KR20040000446A - 중간 용량의 ｌｈｒｈ 길항제를 사용한 치매 및 퇴행성신경질환의 치료 - Google Patents
중간 용량의 ｌｈｒｈ 길항제를 사용한 치매 및 퇴행성신경질환의 치료 Download PDFInfo
- Publication number
- KR20040000446A KR20040000446A KR10-2003-7014128A KR20037014128A KR20040000446A KR 20040000446 A KR20040000446 A KR 20040000446A KR 20037014128 A KR20037014128 A KR 20037014128A KR 20040000446 A KR20040000446 A KR 20040000446A
- Authority
- KR
- South Korea
- Prior art keywords
- use according
- lhrh antagonist
- methyl
- treatment
- lhrh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract description 21
- 206010012289 Dementia Diseases 0.000 title claims abstract description 7
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 5
- 230000003412 degenerative effect Effects 0.000 claims abstract description 5
- -1 3- [benzyl-methyl-amino-methyl] -2-tert-butyl-8- (2-fluoro-benzyl) -6- (3-methoxy-phenyl) -7-methyl-8 H -imidazo [1,2-a] pyrimidin-5-one Chemical compound 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical group C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
- SMWNCXKOTUSXIC-UHFFFAOYSA-N 1-[7-chloro-3-(3,5-dimethylphenyl)-2-oxo-4-(2-piperidin-2-ylethoxy)-1h-quinolin-6-yl]-3-pyridin-2-ylurea Chemical compound CC1=CC(C)=CC(C=2C(NC3=CC(Cl)=C(NC(=O)NC=4N=CC=CC=4)C=C3C=2OCCC2NCCCC2)=O)=C1 SMWNCXKOTUSXIC-UHFFFAOYSA-N 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical group C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- 108010070670 antarelix Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- NVJDXQUSXGIFBO-UHFFFAOYSA-N pentan-3-yl 2-(2,5-dimethylfuran-3-yl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(2-pyridin-2-ylethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylate Chemical compound C12=NC(C3=C(OC(C)=C3)C)=C(CN(C)CCC=3N=CC=CC=3)N2C(=O)C(C(=O)OC(CC)CC)=CN1CC1=CC=CC=C1F NVJDXQUSXGIFBO-UHFFFAOYSA-N 0.000 claims description 2
- 229950011372 teverelix Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 102000009151 Luteinizing Hormone Human genes 0.000 description 5
- 108010073521 Luteinizing Hormone Proteins 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- 239000003163 gonadal steroid hormone Substances 0.000 description 5
- 229940040129 luteinizing hormone Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QGGCIYXVQZHCKK-UHFFFAOYSA-N 3-[[[2-[1-(3,5-difluorophenyl)-3-(2-methoxyphenyl)-1,3-dioxopropan-2-ylidene]-1,3-dihydrobenzimidazol-5-yl]amino]methyl]benzonitrile Chemical compound COC1=CC=CC=C1C(=O)C(C(=O)C=1C=C(F)C=C(F)C=1)=C1NC2=CC(NCC=3C=C(C=CC=3)C#N)=CC=C2N1 QGGCIYXVQZHCKK-UHFFFAOYSA-N 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| US60/287,434 | 2001-04-30 | ||
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040000446A true KR20040000446A (ko) | 2004-01-03 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7014128A Ceased KR20040000446A (ko) | 2001-04-30 | 2002-04-27 | 중간 용량의 ｌｈｒｈ 길항제를 사용한 치매 및 퇴행성신경질환의 치료 |
Country Status (27)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| EP1300398B1 (en) | 2000-07-05 | 2006-04-05 | Astellas Pharma Inc. | Propane-1,3-dione derivatives |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| US7709519B2 (en) * | 2004-06-04 | 2010-05-04 | Astellas Pharma Inc. | Benzimidazolylidene propane-1,3 dione derivative or salt thereof |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| CA2590997A1 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease |
| BRPI0609625A2 (pt) | 2005-03-31 | 2010-04-20 | Astellas Pharma Inc | derivados de propano-1,3-diona ou sal destes |
| BRPI0717618A2 (pt) | 2006-10-21 | 2013-10-22 | Abbott Gmbh & Co Kg | Compostos heterocíclicos e uso dos mesmos como inibidores de glicogênio sintase quinase 3 |
| WO2009043437A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| EP2187917A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| US20110129532A1 (en) * | 2008-05-29 | 2011-06-02 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| EP0901489A1 (en) | 1996-05-20 | 1999-03-17 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| WO2000069859A1 (en) * | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| KR20020045609A (ko) * | 1999-10-15 | 2002-06-19 | 추후기재 | 고나도트로핀-분비 호르몬 수용체 길항제 및 이와 관련된방법 |
| WO2001078780A1 (en) | 2000-04-13 | 2001-10-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for alzheimer's disease |
| EP1300398B1 (en) | 2000-07-05 | 2006-04-05 | Astellas Pharma Inc. | Propane-1,3-dione derivatives |
-
2002
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1575185A (zh) | 2005-02-02 |
| JP2004529207A (ja) | 2004-09-24 |
| EP1392348B1 (en) | 2008-07-09 |
| NZ544417A (en) | 2008-03-28 |
| CZ20033167A3 (cs) | 2004-08-18 |
| US20020177556A1 (en) | 2002-11-28 |
| CA2444876A1 (en) | 2002-12-27 |
| PL362319A1 (en) | 2004-10-18 |
| CN1317030C (zh) | 2007-05-23 |
| ATE400287T1 (de) | 2008-07-15 |
| ZA200305326B (en) | 2003-07-30 |
| NO20034322D0 (no) | 2003-09-26 |
| US7288517B2 (en) | 2007-10-30 |
| WO2002102401A1 (en) | 2002-12-27 |
| RU2319501C2 (ru) | 2008-03-20 |
| IL156777A0 (en) | 2004-02-08 |
| EP1392348A1 (en) | 2004-03-03 |
| UA80679C2 (en) | 2007-10-25 |
| HUP0400067A2 (hu) | 2004-04-28 |
| ES2307760T3 (es) | 2008-12-01 |
| PT1392348E (pt) | 2008-09-09 |
| MXPA03008666A (es) | 2004-10-15 |
| DE60227507D1 (de) | 2008-08-21 |
| AU2002310788B2 (en) | 2007-04-05 |
| BG108339A (bg) | 2004-11-30 |
| DK1392348T3 (da) | 2008-09-29 |
| SK14512003A3 (sk) | 2004-08-03 |
| SI1392348T1 (sl) | 2008-12-31 |
| RU2003134949A (ru) | 2005-02-10 |
| BR0209290A (pt) | 2004-07-13 |
| NO20034322L (no) | 2003-09-26 |
| HK1072000A1 (en) | 2005-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20040000446A (ko) | 중간 용량의 ｌｈｒｈ 길항제를 사용한 치매 및 퇴행성신경질환의 치료 | |
| AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| KR19990067527A (ko) | 동통의 치료를 위한 에피나스틴의 용도 | |
| CN1338939A (zh) | 治疗雄性勃起障碍的组合物 | |
| CZ284363B6 (cs) | Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů | |
| DE69927705T2 (de) | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse | |
| DE60314896T2 (de) | 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| KR20010021851A (ko) | 항통각과민성 아편제의 분무 제형 및 이를 사용하여국소적 통각과민증 및 이에 수반되는 소양증을 치료하는방법 | |
| US20070129423A1 (en) | Method for treating pain | |
| CN1039284C (zh) | 治疗疼痛和增强疼痛解除作用的组合物 | |
| US20070105940A1 (en) | Method for treating pain | |
| EP3529243B1 (en) | (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile for the treatment of endometriosis | |
| HK1072000B (en) | Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists | |
| US12268679B1 (en) | Compositions and methods for epidural administration of MCOPPB for pain relief | |
| US20070259945A1 (en) | Method for treating pain | |
| JPH10500427A (ja) | アレルギー性結膜炎を治療するための２−（４−（アゾリルブチル）−ピペラジニル−メチル）−ベンズイミダゾール誘導体の使用 | |
| WO2019002473A1 (en) | COMPOSITION FOR THE TREATMENT OF ACUTE URINARY RETENTION | |
| US20230321059A1 (en) | Mepyramine for use in the topical treatment of neuropathic pain | |
| EP0998923A1 (en) | Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias | |
| JP2006188496A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤を有効成分とする掻痒治療剤 | |
| AGENT | 46 BAX 3084 | |
| HK1029282A1 (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031028 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20070426 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080102 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20080401 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20080102 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |